Tom Conrad, an independent member of the board since 2017, will fill in as interim CEO. Conrad, who is stepping down as CEO of health platform Zero Longevity Science for the new role at Sonos, has ...

Wall Street analysts are bullish on the sector overall, even after recent pullbacks on interest-rate jitters and the tapering ...

Oil futures were up strongly Monday, with Brent crude on track for its first finish above $80 a barrel since August, as investors assess the potential hit to supply from a further tightening of ...

That’s according to a team at Morgan Stanley led by chief U.S. stock-market strategist Mike Wilson, who told clients that its ...

Littelfuse said its president and chief executive, David Heinzmann, is retiring after four decades with the industrial technology manufacturing company. Littelfuse on Monday said Greg Henderson, a ...

Moderna lost a fifth of its market value as the mRNA vaccine maker after forecasting revenue well below market expectations. Intra-Cellular Therapies stock however soared on a [$15 billion deal to be ...

The company said Monday that it will provide a $119.5 million investment in Truveta's Series C financing round and help launch the company's Truveta Genome Project, which will extend Regeneron's ...

Abercrombie & Fitch raised its sales outlook after posting better-than-expected results in the holiday period, citing a positive consumer response to the company's product selection and its marketing ...

With U.S. stock markets set to open in two hours, Intra-Cellular Therapies Inc. (ITCI) was up 35.7% in pre-market trading, and Zurn Elkay Water Solutions Corp. (ZWS) was up 7.4%.

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

Cineplex said the momentum that began in November thanks to a slate of blockbuster films including "Moana 2" and "Wicked" continued to bring customers to the screens. Wicked is the highest-grossing ...

Shares of Arcutis Biotherapeutics jumped after the company offered fourth-quarter preliminary product revenue results that topped analyst expectations. The stock was up 8% at $14.92 in premarket ...